RFPi, LLC seeks to complete its $3.5 million equity raise in exchange for a 34% stake in the company. RFPi will utilize these funds towards commercializing their technology for imaging blood flow during surgery.
RFPi has already built and tested the initial prototype imaging device and conducted preliminary animal and human trials. RFPi has confirmed the regulatory approval path to be 510k, and plans to submit for FDA approval in Q2.